News

An epidemic of chronic diseases continues to grow in the United States; half the population — an estimated 129 million Americans — have lifelong health conditions that need continuous medical attention and limit certain daily activities.

For all we know about multiple sclerosis (MS) – a chronic disease where a person’s immune system attacks their central nervous system and causes fatigue, bladder issues and pain, among other symptoms – there are still a lot of misconceptions around the condition. Read on to learn what’s fact and what’s fiction when it comes to MS.

When it comes to stroke, it’s crucial to know how to recognize its signs and symptoms so you can access care quickly and preserve brain function. One acronym — BE FAST — can make it easier to identify a stroke, which happens when there’s a blockage to the brain’s blood supply (an ischemic stroke) or a sudden rupture and bleeding in the brain (a hemorrhagic stroke).

BE FAST stands for:

Every February, a very famous football game consumes the general American public. Football is a beloved sport and pastime that celebrates athleticism and teamwork and captures the imaginations of kids who have dreams of going pro. But as The Big Game has grown in size and spectacle over the years, more concern has bubbled up over head injuries, like concussions, in football.

There’s a lot to love about football, but there are also safety factors to consider — as there are with any sport. Here’s what to know about concussions and football.

What is the difference between cardiovascular disease and heart disease?

These two terms are often used interchangeably, but there is a difference. Cardiovascular disease is an umbrella term that encompasses several heart conditions, including heart disease, coronary heart disease, stroke, heart failure and peripheral artery disease.

For neurologists working with patients with Alzheimer’s disease, the road to actual treatment options has been long and paved with setbacks.

But that is changing for some patients. The Food and Drug Administration recently granted full approval to Leqembi® (lecanemab), the first disease-modifying treatment fully approved for patients in the early stages of Alzheimer’s disease. The development of this new drug offers hope to patients and may have lasting impacts on how physicians approach treatment.